Aprea Therapeutics, Inc. Cash and Restricted Cash
Aprea Therapeutics, Inc. (APRE) had Cash and Restricted Cash of $41.28 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-12
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $41.28M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $46.51M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $14.64M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $13.76M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $41.28M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $46.51M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $14.64M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $13.76M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $16.57M 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $19.32M 10-Q · filed 2026-05-13 | |
| 2024-12-31 | $22.89M 10-Q · filed 2026-08-12 | |
| 2024-09-30 | $26.29M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $28.74M 10-Q · filed 2025-08-12 | |
| 2024-03-31 | $32.41M 10-Q · filed 2025-05-14 | |
| 2023-12-31 | $21.65M 10-K · filed 2026-03-16 | |
| 2023-09-30 | $25.39M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $27.73M 10-Q · filed 2024-08-12 | |
| 2023-03-31 | $31.00M 10-Q · filed 2024-05-14 | |
| 2022-12-31 | $28.79M 10-K · filed 2025-03-25 | |
| 2022-09-30 | $33.11M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $39.06M 10-Q · filed 2023-08-10 | |
| 2022-03-31 | $47.65M 10-Q · filed 2023-05-15 | |
| 2021-12-31 | $53.08M 10-K · filed 2024-03-26 | |
| 2021-09-30 | $61.43M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $69.80M 10-Q · filed 2022-08-12 | $69.80M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $77.62M 10-Q · filed 2022-05-16 | |
| 2020-12-31 | $89.02M 10-K · filed 2024-03-26 | |
| 2020-09-30 | $101.15M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $112.86M 10-Q · filed 2021-08-12 | |
| 2020-03-31 | $122.51M 10-Q · filed 2021-05-06 | |
| 2019-12-31 | $130.09M 10-K · filed 2023-03-30 | |
| 2019-09-30 | $52.33M 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $60.99M 10-Q · filed 2020-08-11 | |
| 2019-03-31 | $65.68M 10-Q · filed 2020-05-15 | |
| 2018-12-31 | $65.68M 10-K · filed 2022-03-15 | |
| 2018-09-30 | $12.35M 10-Q · filed 2019-11-14 | |
| 2017-12-31 | $24.40M 10-K · filed 2021-03-16 | |
| 2016-12-31 | $13.67M 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |